Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendao Liu

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Cancer Medicine|January 10, 2024
Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysisYangyang Li, Wendao Liu, Junwei Chen, et al.
Journal of Hepatocellular Carcinoma|July 13, 2026
SPP1+ Macrophages Promote Immunosuppression in Post-TACE Hepatocellular Carcinoma Involving Lactate-Induced Lactylation and Potential SPP1-CD44 SignalingHongyu Wang, Guojun Liang, Ting Liu, et al.
Genes|July 27, 2022
Drug-Target Network Study Reveals the Core Target-Protein Interactions of Various COVID-19 TreatmentsYulin Dai, Hui Yu, Qiheng Yan, et al.
Frontiers in Immunology|February 26, 2024
Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical studyHongyu Wang, Huijie Huang, Ting Liu, et al.
Hepatology International|May 8, 2024
Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysisYangyang Li, Jiandong Guo, Wendao Liu, et al.
La Radiologia Medica|October 6, 2023
A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapyXuelei He, Kai Li, Ran Wei, et al.
International Journal of Surgery (London, England)|September 24, 2025
Identification and validation of an explainable machine learning model for hepatocellular carcinoma with high-risk: a retrospective multicenter cohort studyShufang Hao, Xiaoyu Liang, Xue Li, et al.
Journal of Translational Medicine|June 19, 2026
Resveratrol derivative restores macrophage cholesterol homeostasis via stabilizing xanthine oxidoreductase in hepatocellular carcinomaGuojun Liang, Lin Zeng, Xiaohui Huang, et al.
British Journal of Cancer|July 6, 2024
Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based studyChao An, Ran Wei, Wendao Liu, et al.
International Journal of Surgery (London, England)|December 17, 2025
Resection versus microwave ablation following conversion therapy for unresectable hepatocellular carcinomaHanyu Jiang, Mengxuan Zuo, Ran Wei, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Cancer Medicine|January 10, 2024
Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysisYangyang Li, Wendao Liu, Junwei Chen, et al.
Journal of Hepatocellular Carcinoma|July 13, 2026
SPP1+ Macrophages Promote Immunosuppression in Post-TACE Hepatocellular Carcinoma Involving Lactate-Induced Lactylation and Potential SPP1-CD44 SignalingHongyu Wang, Guojun Liang, Ting Liu, et al.
Genes|July 27, 2022
Drug-Target Network Study Reveals the Core Target-Protein Interactions of Various COVID-19 TreatmentsYulin Dai, Hui Yu, Qiheng Yan, et al.
Frontiers in Immunology|February 26, 2024
Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical studyHongyu Wang, Huijie Huang, Ting Liu, et al.
Hepatology International|May 8, 2024
Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysisYangyang Li, Jiandong Guo, Wendao Liu, et al.
La Radiologia Medica|October 6, 2023
A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapyXuelei He, Kai Li, Ran Wei, et al.
International Journal of Surgery (London, England)|September 24, 2025
Identification and validation of an explainable machine learning model for hepatocellular carcinoma with high-risk: a retrospective multicenter cohort studyShufang Hao, Xiaoyu Liang, Xue Li, et al.
Journal of Translational Medicine|June 19, 2026
Resveratrol derivative restores macrophage cholesterol homeostasis via stabilizing xanthine oxidoreductase in hepatocellular carcinomaGuojun Liang, Lin Zeng, Xiaohui Huang, et al.
British Journal of Cancer|July 6, 2024
Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based studyChao An, Ran Wei, Wendao Liu, et al.
International Journal of Surgery (London, England)|December 17, 2025
Resection versus microwave ablation following conversion therapy for unresectable hepatocellular carcinomaHanyu Jiang, Mengxuan Zuo, Ran Wei, et al.
Pageof 4